cyrilzakka/clinical-trials huggingface dataset:
Vertical Augmentation Using Onlay Versus Inlay Autogenous Graft With Simultaneous Implant Placement.

Using autogenous Chin block for vertical augmentation with simultaneous implant placement at anterior maxilla region comparing between the Onlay and Inlay grafting techniques.

to study the vertical augmentation with simultaneous implant placement at anterior maxillary region.

* P: Patient requires implant at anterior maxillary ridge with vertical deficiency.
* I:Inlay Sandwich Technique with immediate implant placement.
* C:Onlay autogenous graft immediate implant placement.
* O:Outcome name Measuring device Measuring unit

Primary outcome: Vertical bone gain CBCT Millimeter

-Secondary outcome(a): Crestal bone loss CBCT Millimeter

Eligibility Criteria:
Inclusion Criteria:

* \* Patients with partially edentulous anterior maxillary ridges.

  * Patients were free from any systemic disease that interferes with bone healing.
  * Absence of local pathosis at anterior maxillary area.
  * No history of any grafting procedure at the designated edentulous ridge.

The edentulous ridge vertical dimension was less than 10 mm measured from the alveolar crest to the nasal floor (i.e.ridge had vertical inadequacy) with normal horizontal alveolar dimension or patient with Increased Inter-Arch Space.

Exclusion Criteria:

* \* Patient with fully dentulous maxilla.

  * Pregnant females.
  * Presence of bad habits (severe bruxism, clenching).
  * Systemic diseases that may interfere with bone healing.e.g. uncontrolled Diabetes.
Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study

A number of prognostic and/or predictive genomic signatures for breast cancer have been developed by Genome Institute of Singapore (GIS). In the past 1 year, GIS has developed protocols and methods to conduct expression assays from formalin-fixed, paraffin-embedded (FFPE) tumor specimens. A study on 800 tumor samples is planned to analyze these gene signatures and compare them with conventional clinical prognosticators and predictors. As the investigators plan to use archival tumor samples that dates back to the 1990s, the aim of this pilot study is to first analyze 10 anonymized samples to determine the feasibility of running these assays on old archival blocks. The information generated will help us determine whether very old samples (diagnosed before 2000) may be selected for the actual study.

Up to 10 archival breast tumor blocks will be obtained from the Department of Pathology, NUH - half of these blocks will be from patients who were diagnosed before year 2000, and the other half of the blocks will be from patients diagnosed between year 2000-2005 (control specimens). Basic tumor and patient information will be collected without patient identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data. 8-10 ten-micron sections will be cut from each tumor block. RNA will be extracted from the tumor sections using the Roche High Pure FFPE RNA Micro Kit. RNA will be profiled using the Illumina Veracode assay and the Affymetrix Quantigene assay. RNA extraction and gene expression profiling will be performed by collabroators at the Genome Institute of Singapore.

Eligibility Criteria:
Inclusion Criteria:

* Half of these blocks will be from breast cancer patients who were diagnosed before year 2000.
* Half of the blocks will be from breast cancer patients diagnosed between year 2000-2005 (control specimens).

Exclusion Criteria:

* Breast cancer patients diagnosed after year 2005.
Impact of Estrogen on Fear Extinction R61

The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.

The aim of the study was to examine the influence of exogenous estrogen administration on the activation of the fear extinction network in women. Functional MRI data and psychophysiological indices were collected to test the influence of estrogen on women's ability to regulate conditioned fear responses. Women underwent a 3 day experimental paradigm using classical fear conditioning. The first day was conducted outside the scanner, while days 2 and 3 were done inside the fMRI scanner and tested fear extinction learning and recall in days 2 and 3, respectively. The estrogen (or placebo) pill was given just hours before extinction learning test on day 2. No followups were conducted after women completed the 3 day study.

Eligibility Criteria:
Inclusion Criteria:

* Right-handed (Edinburgh Inventory - Oldfield 1971).
* SCID diagnosis consistent with none, current or past history of Axis I psychiatric disorders.
* To be matched for age, gender, and years of education, as well as self-identified race/ethnicity.
* For naturally cycling female subjects, stage of menstrual cycle will be ascertained by history, and by serological measures.
* For women on oral contraceptives, we will identify those using 20mcg ethinyl, 2nd or 3rd generation, monophasic

Exclusion Criteria:

* Psychiatric, neurologic or medical condition that would interfere with study procedures or confound results, ascertained by history.
* History of seizure or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion).
* History of Axis I psychiatric diagnosis; e.g., history of substance use disorder, psychotic disorder, bipolar disorder, tic disorder, or eating disorder.
* Use of psychotropic medication within 4 weeks prior to study (within 6 weeks for fluoxetine, or other long-lived compounds; within one year for neuroleptics).
* Pregnancy (to be ruled out by urine ß-HCG).
* Metallic implants or devices contraindicating magnetic resonance imaging.
* Use of oral contraceptives or non-oral contraceptives containing estrogen and progesterone within 3 months
* History of breast cancer.
* Allergy to peanut oil.
Mom Power is an Attachment Based Parenting Program for Families and Their Children

Mom Power is a weekly attachment based parenting program aimed to increase parenting and self-care skills for families.


Eligibility Criteria:
Inclusion Criteria:

* Participants ages 15+ years with at least one child , interested in learning about parenting and willing to attend weekly sessions in group setting.
* Participants must be willing to be both videotaped and audio taped for research purposes
* must speak English as their first language.

Exclusion Criteria:

* Participants with no children 0-6 or younger than 15. Participants not willing to attend weekly sessions or participate in group/at home control.
USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY

This study is created in order to refine and reduce the duration between the medical and surgical therapeutic sequences (when the surgery is necessary) in these fragile patients knowing that conventional radiological changes can only be observed with a delay comprised between 3 and 6 months starting from observed clinical changes.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with symptomatic osteoradionecrosis with a PENTOCLO protocol indication (decided in a multi-disciplinary staff).
2. Patient should understand to any protocol-specific procedures performed. Patient who did not object to participate after being informed of the study. Patient should be able and willing to comply with study visits and procedures as per protocol.
3. Patients must be affiliated to a social security system or beneficiary of the same.
4. Patients must be over 18 years old (legal age).

Exclusion Criteria:

1. Excluded forms of the disease: mandibular osteoradionecrosis complicated by mandibular fracture and / or hyperalgesic (resistant to analgesic treatment of stage III).
2. Contraindications specific to the treatment under study (allergy to one of the PENTOCLO treatments, contraindication to 18FDG PET-CT).
3. Associated pathology that contra-indicate on of the PENTOCLO treatment.
4. Pregnant woman, declaring likely to be pregnant or breastfeeding. Chilbearing age women must declare not being pregnant and use effective contraception.
5. Impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons.
6. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or unable to express its opposition to participating in the study.
The Spraino Pilot Trial

This pilot study will establish the preliminary effect and safety of using Spraino® to prevent lateral ankle sprains amongst athletes competing in indoor sports at sub-elite level, with a one-year follow-up.

All recruited participants will have a history of lateral ankle sprain in the preceding 24 months prior to the initiation of the trial. Half of the included participants will receive Spraino® to prevent lateral ankle sprains (intervention group). The other half will receive no intervention ("do-as-usual" control group). Both groups will be permitted to continue or initiate any usual care of their choice, except Spraino® in the control group. Short Message Services (SMS) will be used for registration of injury and exposure.

The purpose of this exploratory trial (named "The Spraino Pilot Trial") is to establish the preliminary effect and safety of using Spraino® to prevent lateral ankle sprains amongst athletes competing in indoor sports at sub-elite level (handball, basketball, floorball and badminton) when compared to a "do-as-usual" control group.

It is a randomized controlled pilot trial (Pilot-RCT) with a two-group parallel design and blinded outcome assessment. The trial will include prospective injury and exposure registration using a Short Message Services-system (SMS-Track) throughout a 52-week follow-up period (one calendar year).

It is anticipated that 500 participants, which approximates to 250 in each group, will be enrolled in the trial. The enrollment process will cease when at least 250 participants have been allocated to the intervention group. Only athletes participating in indoor sports with a history of a lateral ankle sprain in the preceding 24 months are eligible for inclusion in the trial. The participants will be randomized (1:1 allocation ratio) using numbered lots. The randomization process will ensure stratification for gender, sports discipline and level of play.

A full trial protocol, based on the "SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials" (Chan et al., 2013) and the "PREPARE Trial guide" (Bandholm et al., 2017), will be published and made publicly available. The trial report will adhere to the CONSORT 2010 statement, using the extension for randomized pilot and feasibility trials.

Being an exploratory pilot trial, the study is designed with a flat outcome structure with multiple evenly valued outcome measures. Thus, no primary and secondary outcome measure hierarchy exists.

Eligibility Criteria:
Inclusion Criteria:

* Participant is ≥ 18 years old at commencement of trial.
* Participant can read, speak and understand Danish.
* Participant can receive and reply to texts on a cell phone using Short Message Services (SMS).
* Participant performs indoor sports (Handball, basketball, floorball orbadminton) in a sub-elite level team with ≥ 2 weekly practice sessions.
* Participant has incurred ≥ 1 lateral ankle sprain injury in the preceding 24 months.
* Participant has returned to play at commencement of the trial.
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with AK of the face or scalp
* Has clinically typical, visible, and discrete AK lesions
* Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK
* Willing to avoid excessive sun or ultraviolet (UV) exposure, and/or use relevant sunscreen protection and protective clothing during the study duration
* Able to read and write English
* Provide consent to participate in the study
* Willing to comply with all study procedures and be available for the duration of the study

Exclusion Criteria:

* Participants with any dermatological condition of the face or scalp that could interfere with the clinical evaluations.
* Hypertrophic AK lesions, open wounds or suspected skin cancers within close proximity of the treatment area.
* Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
* Participants unable to comply with the requirements of the study or participants who in the opinion of the study physician should not participate in the study.
* Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.


Eligibility Criteria:
Inclusion Criteria:

* Pathologically-confirmed diagnosis of NHL or RCC
* Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy
* Confirmed CD70 expression
* Measurable disease, defined as at least 1 lesion \>1.5 cm in the greatest transverse diameter for patients with NHL, and at least 1 non-resectable tumor lesion \> or equal to 10 mm in diameter for patients with RCC

Exclusion Criteria:

* Previously received an allogeneic transplant
* History of another primary malignancy that has not been in remission for at least 3 years
* Prior anti-CD70-directed therapy
Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens

This study evaluates an educational web-based intervention designed to increase adolescent boys' and girls' motivation and skills to engage in safer sexual behavior (HEART: Health Education and Relationship Training). Half of participants will receive HEART and half of participants will receive Growing Minds, an attention-matched control website focused on growth mindsets of intelligence and self-regulation. The ultimate goal of this work is to help youth reduce their risk of HIV and other sexually transmitted diseases and to avoid unplanned pregnancies.

This study evaluates an educational web-based intervention designed to increase adolescent boys' and girls' motivation and skills to engage in safer sexual behavior (HEART: Health Education and Relationship Training). Half of participants will receive HEART and half of participants will receive Growing Minds, an attention-matched control website focused on growth mindsets of intelligence and self-regulation. The ultimate goal of this work is to help youth reduce their risk of HIV and other sexually transmitted diseases and to avoid unplanned pregnancies.

Primary outcomes for this study include 1) acceptability of the program, 2) safer sex self-efficacy, and 3) safer sex intentions.

Eligibility Criteria:
Inclusion Criteria:

* 10th or 11th grader
* Able to read English

Exclusion Criteria:

* None
Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease_part1

The purpose of this trial is to test the effects of a personalized music intervention (Music and Memory, Inc.) on agitated and aggressive behaviors for nursing home residents with dementia.

The purpose of this study is to conduct a parallel, pragmatic, cluster randomized control trial of personalized music (Music and Memory) for nursing home residents with moderate to severe dementia living in 54 nursing homes (27 treatment, 27 control) from 4 nursing home corporations. Music and Memory is a personalized music program that uses portable music players to deliver individualized music to people with dementia at times when agitated behaviors are likely.

\*\*This funding mechanism sponsored two parallel trials with different implementation strategies. In this trial, nursing home staff identify the music a resident with dementia may have preferred when s/he was young by asking family members and testing individual songs with the resident. Details of the second parallel trial conducted under this funding mechanism are registered under "R33AG057451_part2."\*\*

The aims of this study are: 1. To use a train-the-trainer model to implement the intervention with ongoing monitoring of the program's adoption and acceptance by nursing home residents with dementia; 2. To estimate the impact of Music and Memory on agitated and aggressive behaviors; and 3. To examine factors associated with variation in providers' adherence to the implementation of Music and Memory.

Eligibility Criteria:
Inclusion Criteria for Nursing Homes:

* Owned by partnering health care corporations
* Medicare / Medicaid-certified
* Have at least 20 eligible residents

Inclusion Criteria for Residents in Eligible Nursing Homes

* Reside in eligible nursing home for last 90 days
* Have advanced dementia, defined by the presence of a dementia diagnosis and moderately or severely impaired daily decision-making

Exclusion Criteria for Nursing Homes:

* recent situations that may affect implementation (for example, bad state or federal quality assurance surveys, leadership turnover, or other competing demands)
* previous use of Music and Memory

Exclusion Criteria for Residents in Eligible Nursing Homes:

* dislikes music
* completely deaf
Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®

The study was carried out as a prospective, non-interventional study with the intention of subsequent process cost analyses (PCA) and also considers quality of life, drug misuse, dependence, adverse events and therapy satisfaction.

The study was carried out as a prospective, non-interventional study with the intention of subsequent process cost analyses (PCA) and also considers quality of life, drug misuse, dependence, adverse events and therapy satisfaction. Data were collected in collaboration with 22 physicians in Germany.

The study was designed as a one armed non-interventional study. Patients had to suffer from nervous restlessness in order to be eligible for study documentation. Participants agreed to a medical treatment with PASCOFLAIR® of 12 weeks. In this context, documented patients could take PASCOFLAIR® at the first time or could have started within the past three months before the initial visit. Furthermore, documented patients had to be older than 18 years and must be able to read and understand the patient declaration of data protection and the declaration of consent. The patient must not be an alcoholic, must not be drug dependent and have no other types of addiction. Patients who were pregnant or breast-feeding were not eligible for study participation. Furthermore, patients showing hypersensitivity against passionflower extract or against other components of the medication were excluded. The signed declaration of consent of participating patients is available.

The treatment of affected patients may not be documented, if a redemption (written or spoken) of the declaration of consent is existing or the patient takes Benzodiazepines.

Eligibility Criteria:
Inclusion Criteria:

* patients suffering from nervous restlessness

Exclusion Criteria:

* Age \< 18 years and must be able to read and understand the patient declaration of data protection and the declaration of consent
* alcoholics, drug pending, addictive disorder
* pregnancy or lactating
* patients showing hypersensitivity against passionflower extract or against other components of the medication
A Prospective Cohort of Patients With Cervical/Intracranial Arteries Stenosis in China

The aim of this study is to establish a prospective cohort of patients with cervical/intracranial arteries stenosis in China.

A prospective cohort of patients with cervical/intracranial arteries stenosis from various regions of China will be established. This prospective cohort is used to identify the distribution of risk factors in the patients with cervical/intracranial arteries stenosis.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 40 and ≤ 80 years;
2. Ultrasound or imaging examinations indicating cervical artery stenosis and/or intracranial artery stenosis (including mild, moderate, severe stenosis, or occlusion);
3. Willing to participate and signing the informed consent form.

Exclusion Criteria:

1. Patients with stroke occurring within the past year;
2. Patients with severe systemic diseases, such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation disorders, malignancies, etc.;
3. Patients with a life expectancy of less than one year or those who are unable to complete the study for other reasons.
Compliance of Traditional Chinese Medicine in Young Patients With Rheumatic Diseases

To evaluate the compliance of traditional Chinese medicine (TCM) in young people with Chronic rheumatic disease


Eligibility Criteria:
Inclusion Criteria:

* were between 18 and 35 years of age
* without use of TCM in the previous 3 months
* and had a Steinbrocker functional status of class I, II, or III

Exclusion Criteria:

* previous general health conditions disallowed their use of TCM
* were pregnant
* lack of motivation, remote from home, time-consuming,intervention, or other personal difficulties
Perioperative Personalized Blood Pressure Management

The investigators propose a pilot trial to (1) proof the concept that defining the intraoperative mean arterial pressure (MAP) intervention threshold based on the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring) results in clinically relevant (mean nighttime MAP ± 10 mmHg) different target values compared with using an absolute population-derived MAP intervention threshold of 65 mmHg (primary endpoint); (2) investigate if a personalized perioperative blood pressure management is feasibly in multi-center studies, especially if the target values can be sufficiently achieved (secondary endpoint); (3) study the impact of personalized perioperative blood pressure management on the incidence of myocardial injury after non-cardiac surgery (MINS) (exploratory endpoint); (4) study the impact of personalized perioperative blood pressure management on the incidence of acute kidney injury within the first three postoperative days according to the KDIGO (Kidney Disease: Improving Global Outcomes) definition without oliguric criteria (exploratory endpoint).

not provided

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 45
* American Society of Anesthesiologists physical status class (ASA) II-IV
* scheduled for elective major surgery under general anesthesia
* surgery expected to last ≥ 120 minutes

Exclusion Criteria:

* emergency surgery
* patients having liver or kidney transplantation
* laparoscopic surgery
* pregnancy
* status of post transplantation of kidney, liver, heart, or lung
* sepsis (according to current Sepsis-3 definition)
* impossibility of preoperative automated blood pressure monitoring
* MAP differences between the right and the left arm of more than 20 mmHg surgery that requires controlled hypotension